止嗽散加味治疗慢性支气管炎急性发作合并2型糖尿病临床研究

Clinical Effect of Modified Zhisou San(止嗽散加味) in the Treatment of Acute Exacerbation of Chronic Bronchitis with T2DM

目的探讨止嗽散加味对慢性支气管炎急性发作合并2型糖尿病患者的临床疗效及炎性因子水平的影响。方法选取2017年9月—2019年2月于辽阳市中医院就诊治疗的慢性支气管炎急性发作合并2型糖尿病患者104例,随机分为观察组与对照组,每组各52例,对照组患者接受常规西医治疗,观察组患者在对照组基础上服用止嗽散加味治疗,并于治疗结束后观测两组患者的治疗有效率、肺功能[用力肺活量(FVC)、第一秒用力呼气容积占预计值百分比(FEV1/Pre)、第一秒用力呼气容积占用力肺活量比值(FEV1/FVC)]、糖代谢指标[空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)]、生活质量评分及血清炎性因子[超敏C反应蛋白(hs-CRP)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]水平。结果治疗后观察组患者有效率显著高于对照组(P<0.05)。治疗后观察组患者肺功能指标(FVC、FEV1/Pre、FEV1/FVC)、生活质量评分显著高于对照组(P<0.05),且糖代谢指标(FPG、2 h PG、HbA1c)、血清炎性因子(hs-CRP、IL-6、TNF-α)水平显著低于对照组(P<0.05)。结论止嗽散加味能够明显提高慢性支气管炎急性发作合并2型糖尿病患者肺功能水平,降低患者糖代谢水平及血清炎性因子IL-6、TNF-α、hs-CRP表达,改善患者生活质量,临床治疗效果显著且安全性高,值得临床推广应用。

Objective To explore the clinical efficacy of Modified Zhisou San (止嗽散加味) in the treatment of acute exacerbation of chronic bronchitis with type 2 diabetes mellitus and the level of serum inflammatory factors. Methods 104 patients of acute exacerbation of chronic bronchitis with type 2 diabetes mellitus were randomly divided into the observation group and the control group,52 patients in each group. The control group received conventional western medicine treatment. The observation group received Modified Zhisou San on the basis of the control group. The treatment rate,lung function [forced vital capacity(FVC),forced expiratory volume in one second/prediction(FEV1/Pre),ratio of forced expiratory volume to forced vital capacity in the first second(FEV1/FVC),glycometabolism levels [fasting plasma glucose(FPG),2 hours postprandial blood glucose(2 h PG),glycosylated hemoglobin(HbA1 c)],quality of life questionnaire score and the level of serum inflammatory factors[hypersensitive C-reactive protein(hs-CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)] before and after treatment. Results After treatment,the effective rate of the observation group was significantly higher than that of the control group(P<0.05). After treatment,the levels of lung function(FVC,FEV1/Pre,FEV1/FVC)and quality of life questionnaire score in the observation group were higher than those in the control group(P<0.05). After treatment,the glycometabolism levels(FPG,2 h PG,HbA1c)and the levels of serum inflammatory factors(hs-CRP,IL-6,TNF-α)in the observation group were significantly lower than those in the control group(P<0.05). Conclusion Modified Zhisou San can obviously improve the lung function level,reduce the level of glucose metabolism and the expression of serum inflammatory factors(hs-CRP,IL-6,TNF-α),improve the quality of life in patients of acute exacerbation of chronic bronchitis with type 2 diabetes,significantly improve the treatment efficiency and high safety,which is worthy of clinical application.